Summary: Creatine is globally recognized as a staple gym supplement sold by the tub to build lean muscle and boost athletic performance. However, because the human brain runs on the exact same cellular bioenergetics as skeletal muscle, neuroscientists have increasingly wondered if the compound’s energy-boosting properties can operate above the neck to treat mood disorders.
A pioneering systematic review investigated this quiet possibility, executing a rigorous clinical audit of existing data to ask a fundamental question: Can creatine serve as an effective therapeutic intervention for depression?
Key Facts
- The Neuroenergetic Hypothesis: The brain is a metabolically demanding organ, consuming a massive share of the body’s energy relative to its size. Mood disorders are frequently linked to altered creatine metabolism and impaired cellular energy production, making the restoration of adenosine triphosphate (ATP) via creatine a highly logical therapeutic target.
- The Success Signals: Two trials drawn from a study of women with major depressive disorder showed that adding 5 g of creatine daily to the antidepressant escitalopram produced a massive therapeutic drop in symptoms compared to a placebo, achieving an impressive Cohen’s d effect size of 1.13. Another trial saw a steep decrease in symptoms when pairing creatine with cognitive behavioral therapy (CBT).
- The Null Findings: Conversely, three trials reported zero clinical benefit. Creatine failed to alleviate symptoms in patients who were already treatment-resistant to standard medications, generated no statistical difference in adolescent girls, and showed no effect in individuals experiencing depressive episodes linked to bipolar disorder.
- The Bipolar Mania Warning: Crucially, two patients with bipolar disorder who received creatine developed hypomania or mania during the trial. This safety signal serves as a sobering medical reminder that shifting cellular energy pathways can induce volatile adverse events depending on a patient’s underlying psychiatric architecture.
- The Sex Dependency Clue: Preclinical animal research indicates that creatine alters depression-like behavior differently in male and female rodents. This biological divergence may explain why the human trials that enrolled exclusively female cohorts yielded the most significant clinical success.
- Safety & Gastrointestinal Profile: Outside of the critical mania risk isolated in the bipolar cohort, creatine maintained an exceptionally high safety profile across the trials, with adverse events strictly limited to mild gastrointestinal discomfort.
Source: Genomic Press
Walk into any gym supplement aisle and creatine is there, sold by the tub to people chasing bigger muscles. It is one of the most studied compounds in sports science. What far fewer people know is that the brain runs on much the same chemistry the muscles do, and that the energy creatine helps supply may matter just as much above the neck as below it.
A new systematic review, published today in Brain Medicine, takes that quiet possibility seriously and asks a hard question. Can creatine help treat depression?
What the Researchers Looked At
The team behind the review, led by Bassam Jeryous Fares of the University of Ottawa, did not run a new trial. They gathered the ones that already existed. After screening the literature, they settled on six published reports describing five randomized controlled trials, the kind of study in which neither patient nor doctor knows who received the real compound and who received a placebo.
Those trials had been conducted across five countries, in South Korea, the United States, Brazil, Israel, and India, and together they enrolled 238 participants at baseline, 126 on creatine and 112 on placebo. The average age was 36 years. Most participants were women. Two of the trials enrolled women only.
Four of the trials studied major depressive disorder. One studied people with bipolar disorder who were living through a depressive episode. Because the studies differed so widely in design, the authors did not pool the numbers into a single statistic. They summarized them in narrative instead, letting each trial speak for itself.
A Split Decision
Here is where the story refuses to resolve cleanly. Two of the five trials, both drawn from the same study of women with major depressive disorder, found real benefit. When five grams of creatine per day was added to the antidepressant escitalopram, depressive symptoms fell further than they did on placebo after eight weeks. The effect was large by the usual statistical yardsticks, with a Cohen’s d of 1.13 on the Hamilton Depression Rating Scale, and more women reached remission. A separate trial paired creatine with cognitive behavioral therapy and saw a steeper drop in symptoms on a standard questionnaire than therapy plus placebo produced.
Then the picture darkens. The remaining three trials found nothing. One saw no effect of creatine, at five or ten grams daily, in people who had already failed to respond to medication. Another, testing several doses in adolescent girls, found no difference from placebo.
The last looked at people with bipolar disorder in a depressive episode and again found no treatment benefit. Worse, two of those bipolar patients taking creatine developed hypomania or mania, a sober reminder that the same compound can behave very differently depending on the diagnosis.
Why Creatine Might Matter for the Brain
The logic behind the experiments is not far fetched. The brain is an expensive organ, burning energy at a rate out of all proportion to its size, and creatine helps cells rebuild adenosine triphosphate, the molecule that pays for that work. Studies of people with mood disorders have found altered creatine metabolism in the brain, and impaired energy production has been proposed as one root of depression.
Creatine may also nudge the pathways that govern dopamine and serotonin, the neurotransmitters that most antidepressants target. The authors are careful here. They note that the link between brain creatine and mood remains correlational, not proven cause and effect, and that the biology of depression has many moving parts.
“The signal is interesting, but it is not a verdict,” said Bassam Jeryous Fares, first author of the review and a student in the Faculty of Medicine at the University of Ottawa. “Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice. It is the kind that tells you the question is worth further exploration.”
Nicholas Fabiano, corresponding author and a psychiatry resident at the University of Ottawa, framed the work as a starting point rather than a conclusion. “Creatine appears to be a safe intervention. The adverse events we found were limited to mild gastrointestinal discomfort. We cannot yet reliably say that creatine helps with depressive symptoms or if the findings are generalizable to everyone.”
What Comes Next
The review does not pretend to settle the matter. The authors flag the obvious limitations. The trials were small. The sexes were unbalanced, with two studies enrolling only women. The quality varied, with two trials judged at low risk of bias and three carrying some concern, arising mostly from how patients were assigned and how missing data were handled. The findings, the authors stress, are not yet generalizable.
What they call for is more rigorous work. Larger trials. Longer ones, running past the eight week mark. Studies that test creatine alongside exercise, and studies that explore higher doses, while keeping in mind that more is not always better. There is even a tantalizing clue from animal research, where creatine altered depression like behavior differently in male and female rodents, which may help explain why the human trials with more women showed more promise. For now, creatine remains a promising lead rather than a proven remedy. The molecule that builds muscle has earned a closer look from the people who study the mind.
Key Questions Answered:
A: Even though we associate creatine with weightlifters, your brain is actually a massive energy hog, burning a wildly disproportionate amount of the body’s fuel to keep your thoughts, neurons, and synapses firing. Cells pay for this intense workload using a molecular currency called adenosine triphosphate (ATP). Creatine acts like a rapid-charging battery station, helping brain cells rebuild spent ATP on the fly. Because modern neuro-imaging frequently discovers broken energy production and altered creatine metabolism inside the brains of depressed patients, scientists hypothesized that supplementing with creatine could essentially “jump-start” the brain’s struggling power plants.
A: This “split decision” is exactly why depression is so notoriously difficult to treat—it isn’t a single, uniform disease. The systematic review showed that creatine worked exceptionally well when paired with standard antidepressants in adult women, yet flopped in treatment-resistant patients and adolescent girls. This suggests that creatine’s success depends heavily on variables like a patient’s hormonal profile, biological sex, and age. Furthermore, animal research has confirmed that creatine shifts depressive behaviors differently in male versus female brains, meaning the high concentration of women in the successful trials likely tipped the scales toward a positive result.
A: While creatine is incredibly safe for the general public, typically causing nothing more than mild stomach discomfort, this review uncovered a critical, urgent safety warning for individuals with bipolar disorder. Two patients in the bipolar group who took creatine were rapidly pushed out of their depression and directly into states of hypomania or full clinical mania. Because creatine alters the brain’s baseline energy dynamics and can nudge neurotransmitters like dopamine and serotonin, it can behave like a wild card. No one dealing with a diagnosed mood disorder should ever self-prescribe creatine without direct, close supervision from their psychiatrist or healthcare team.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this depression research news
Author: Ma-Li Wong
Source: Genomic Press
Contact: Ma-Li Wong – Genomic Press
Image: The image is credited to Neuroscience News
Original Research: The findings will appear in Brain Medicine
